Transplant infectious disease : an official journal of the Transplantation Society 2018 03 23() e12883 doi 10.1111/tid.12883
Some studies have suggested that rATG treatment may be associated with an increased incidence of CMV infection and delayed CMV immune response. However, the evidences supporting this matter are scarce. This study aims to characterize the kinetic of the CMV-specific T-cell immune response before and after rATG induction therapy and the relationship with the development of CMV infection in CMV-seropositive kidney transplant recipients.
An observational prospective study of CMV-seropositive kidney transplant patients that received rATG induction therapy was performed. A pretransplant sample was obtained before the surgery to determine the CMV-specific immunity. CMV viral load (by PCR) and CMV-specific T-cell immune response (by flow cytometry) were determined during the follow-up at 0.5, 1, 2, 3, 6 and 12 months post-transplantation.
A total of 23 patients were included in the study. CMV prophylaxis was administrated for a media of 90 days after transplantation. At the end of follow-up, 18 (78.3%) patients had CMV-specific immunity with a median value of 0.31% CD8CD69INF-γT-cells at a median of 16 weeks post-transplantation. Five patients never acquired CMV-specific immunity. No statistically significant association between CMV infection and CMV-specific T-cell immune response (P=0.086) was observed. However, patients with positive pretransplant CMV-specific immunity developed earlier immunity and achieved higher levels of CD8CD69INF-γ+ T-cells post-transplantation than patients with negative pretransplant immunity.
CMV-specific immune monitoring in addition to CMV-serology may be useful to stratify patient’s risk of CMV infection before transplantation. This article is protected by copyright. All rights reserved.